Wound bed and biofilm

The wound bed and biofilm represent a complex and dynamic microenvironment that serves as a primary barrier to healing in chronic wounds, such as diabetic foot and pressure ulcers. Biofilms are organized aggregates of microorganisms embedded in a self-produced extracellular polymeric substance (EPS) that confers high resistance to both host immunity and conventional antibiotics (PubMed, PMID: 30126413). The wound bed consists of the host tissue surface, which in chronic cases often suffers from persistent inflammation and excessive protease activity that degrades the host's extracellular matrix (StatPearls, NBK482254). Pharmacological interventions are directed at 'Wound Bed Preparation' (WBP), a clinical framework involving debridement, moisture control, and the use of biofilm-disrupting agents like cadexomer iodine or silver-based dressings to reduce bioburden and foster a regenerative environment (PubMed, PMID: 28166453). Because this entity is a multi-species microbial ecosystem integrated with damaged host tissue rather than a single molecular entity, it is categorized as a clinical site or pathological microenvironment for drug delivery and management.

Other names

Woundbed and biofilmWound biofilmChronic wound microenvironmentInfected wound bedBiofilm-associated wound

Therapeutic management involves the physical and chemical disruption of the microbial extracellular polymeric substance (EPS) matrix to expose sequestered bacteria to antimicrobials and the host immune system. Antimicrobial agents like silver and iodine exert oxidative stress and inhibit microbial enzymes, while enzymatic debriders remove necrotic host tissue that serves as a scaffold for biofilm growth.